Collaboration to develop novel, next-generation
therapeutics to treat heart disease
Takeda Pharmaceutical Company Limited (TSE: 4502) and Cardurion
Pharmaceuticals today announced the creation of a new
cardiovascular development partnership. Cardurion, a recently
launched Boston-area based biotechnology company, is focused on the
development of novel, next-generation therapeutics for the
treatment of heart failure and other cardiovascular diseases.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20170802005176/en/
Cardurion is led by two physician scientists with extensive
experience in cardiovascular science, medicine and drug development
-- Daniel Bloomfield, M.D., chief executive officer, and Michael
Mendelsohn, M.D., founder and executive chairman. Takeda will
jumpstart the new company’s discovery efforts by providing a
12-person cardiovascular research team from its Shonan, Japan site,
including fully equipped laboratory space, development resources
and licenses to a portfolio of preclinical-stage cardiovascular
drug programs.
“The creation of this partnership with Cardurion follows
Takeda’s strategy to leverage external innovation by placing
selected assets and outstanding scientists into entrepreneurial
environments,” said Andrew Plump, M.D., Ph.D., chief medical and
scientific officer, Takeda. “By leveraging the high level of
therapeutic expertise at Takeda’s Shonan Research Center to support
drug discovery, we’re motivating scientists to come together to
deliver on our promise of serving patients with existing unmet
needs.”
The newly formed Cardurion is headquartered in Cambridge,
Massachusetts and has research facilities in Shonan, Japan -- with
both locations surrounded by leading academic research ecosystems
that support biotechnology and pharmaceutical companies.
“This partnership demonstrates our shared commitment to
developing transformative, novel therapies that can have a
meaningful impact for the millions of people around the world
suffering from heart disease,” said Bloomfield. “The scientific
collaboration we’re establishing with Takeda will propel our
preclinical efforts and ultimately help get important therapies
into the hands of patients in need.”
Cardiovascular disease is the leading cause of death worldwide
in both men and women, accounting for more than 17 million deaths
per year1, a number that is expected to grow to nearly 24 million
by 20302. Heart failure alone affects more than six million
patients in the U.S.3, with nearly a million new patients diagnosed
each year3.
About Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited is a global, research and
development-driven pharmaceutical company committed to bringing
better health and a brighter future to patients by translating
science into life-changing medicines. Takeda focuses its R&D
efforts on oncology, gastroenterology and central nervous system
therapeutic areas plus vaccines. Takeda conducts R&D both
internally and with partners to stay at the leading edge of
innovation. New innovative products, especially in oncology and
gastroenterology, as well as Takeda’s presence in Emerging Markets,
are currently fueling the growth of Takeda. More than 30,000 Takeda
employees are committed to improving quality of life for patients,
working with Takeda’s partners in health care in more than 70
countries. For more information,
visit http://www.takeda.com/news.
About Cardurion Pharmaceuticals
Cardurion is a biotechnology company focused on the development
of novel, next-generation therapeutics for the treatment of heart
failure and other cardiovascular diseases. The company has
facilities in Cambridge, Massachusetts and Shonan, Japan. For more
information, visit http://www.cardurion.com.
Takeda’s Forward-Looking Statements
This press release contains “forward-looking statements.”
Forward-looking statements include all statements other than
statements of historical fact, including plans, strategies and
expectations for the future, statements regarding the expected
timing of filings and approvals relating to the transaction, the
expected timing of the completion of the transaction, the ability
to complete the transaction or to satisfy the various closing
conditions, future revenues and profitability from or growth or any
assumptions underlying any of the foregoing. Statements made in the
future tense, and words such as “anticipate,” “expect,” “project,”
“continue,” “believe,” “plan,” “estimate,” “pro forma,” “intend,”
“potential,” “target,” “forecast,” “guidance,” “outlook,” “seek,”
“assume,” “will,” “may,” “should,” and similar expressions are
intended to qualify as forward-looking statements. Forward-looking
statements are based on estimates and assumptions made by
management that are believed to be reasonable, though they are
inherently uncertain and difficult to predict. Investors and
security holders are cautioned not to place undue reliance on these
forward-looking statements.
Forward-looking statements involve risks and uncertainties that
could cause actual results or experience to differ materially from
that expressed or implied by the forward-looking statements. Some
of these risks and uncertainties include, but are not limited to:
required regulatory approvals for the transaction may not be
obtained in a timely manner, if at all; the conditions to closing
of the transaction may not be satisfied; competitive pressures and
developments; applicable laws and regulations; the success or
failure of product development programs; actions of regulatory
authorities and the timing thereof; changes in exchange rates; and
claims or concerns regarding the safety or efficacy of marketed
products or product candidates in development.
The forward-looking statements contained in this press release
speak only as of the date of this press release, and neither
Cardurion, nor Takeda undertake any obligation to revise or update
any forward-looking statements to reflect new information, future
events or circumstances after the date of the forward-looking
statement. If one or more of these statements is updated or
corrected, investors and others should not conclude that additional
updates or corrections will be made.
Cardurion’s Forward Looking Statements
This press release contains forward-looking statements, all of
which are qualified in their entirety by this cautionary statement.
Any statements contained herein that do not describe historical
facts, including, but not limited to, statements that express or
imply future outcomes of our partnership with Takeda, are
forward-looking statements that are based on management's
expectations and are subject to certain factors, risks and
uncertainties that may cause actual results, outcomes, timing and
performance to differ materially from those expressed or implied by
such statements. These factors, risks and uncertainties include,
but are not limited to: the costs and uncertainties associated with
our research efforts and other discovery activities; the inherent
uncertainties associated with the conduct, timing and results of
preclinical and clinical studies of our product candidates; and the
adequacy of our capital resources and availability of additional
funding. Except as otherwise noted, these forward-looking
statements speak only as of the date of this press release, and we
undertake no obligation to update or revise any of such statements
to reflect events or circumstances occurring after this press
release. We caution readers not to place undue reliance on the
forward-looking statements contained in this press release.
1 World Health Organization. Cardiovascular Diseases Fact Sheet.
May 2017. Retrieved June 2017.2 World Health Organization. About
Cardiovascular Diseases. Retrieved June 2017.3 Centers for Disease
Control and Prevention. Heart Failure Fact Sheet. Retrieved July
2017.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170802005176/en/
Media Contacts for Takeda:Tsuyoshi Tada –
Japantsuyoshi.tada@takeda.com+81-3-3278-2417orKelly Schlemm –
USAkelly.schlemm@takeda.com+1-617-551-8865orMedia Contact for
Cardurion:Pure CommunicationsStephanie
Huttonshutton@purecommunications.com+1 910.726.1367